Andrew R Pettitt

Andrew R Pettitt

UNVERIFIED PROFILE

Are you Andrew R Pettitt?   Register this Author

Register author
Andrew R Pettitt

Andrew R Pettitt

Publications by authors named "Andrew R Pettitt"

Are you Andrew R Pettitt?   Register this Author

44Publications

687Reads

-Profile Views

Central nervous system plasmablastic lymphoma evolving from polyclonal plasmacytosis.

Br J Haematol 2018 Nov 9;183(3):345. Epub 2018 Jul 9.

Haemato-oncology Diagnostic Service, Liverpool Clinical Laboratories, Liverpool, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.15489DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6282794PMC
November 2018

Genome-wide association analysis implicates dysregulation of immunity genes in chronic lymphocytic leukaemia.

Nat Commun 2017 02 6;8:14175. Epub 2017 Feb 6.

Department of Health Sciences Research, Mayo Clinic, Rochester, Minnesota 55905, USA.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/ncomms14175DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5303820PMC
February 2017

Total proteome analysis identifies migration defects as a major pathogenetic factor in immunoglobulin heavy chain variable region (IGHV)-unmutated chronic lymphocytic leukemia.

Mol Cell Proteomics 2015 Apr 2;14(4):933-45. Epub 2015 Feb 2.

From the ‡Department of Molecular and Clinical Cancer Medicine, ¶Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool L7 8XP, UK

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1074/mcp.M114.044479DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4390271PMC
April 2015

Expression of functional sphingosine-1 phosphate receptor-1 is reduced by B cell receptor signaling and increased by inhibition of PI3 kinase δ but not SYK or BTK in chronic lymphocytic leukemia cells.

J Immunol 2015 Mar 28;194(5):2439-46. Epub 2015 Jan 28.

Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L69 3GA, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1402304DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4337486PMC
March 2015

Selective IAP inhibition results in sensitization of unstimulated but not CD40-stimulated chronic lymphocytic leukaemia cells to TRAIL-induced apoptosis.

Pharmacol Res Perspect 2014 Dec 1;2(6):e00081. Epub 2014 Sep 1.

Department of Molecular and Clinical Cancer Medicine, University of Liverpool Liverpool, United Kingdom ; Royal Liverpool & Broadgreen University Hospitals NHS Trust Liverpool, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1002/prp2.81DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4186455PMC
December 2014

Assessment of TP53 functionality in chronic lymphocytic leukaemia by different assays; an ERIC-wide approach.

Br J Haematol 2014 Nov 30;167(4):565-9. Epub 2014 Jun 30.

Department of Haematology, Academic Medical Centre, Amsterdam, The Netherlands; Laboratory of Exp. Immunology, Academic Medical Centre, Amsterdam, The Netherlands.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13006DOI Listing
November 2014

Loss of MIR15A and MIR16-1 at 13q14 is associated with increased TP53 mRNA, de-repression of BCL2 and adverse outcome in chronic lymphocytic leukaemia.

Br J Haematol 2014 Nov 18;167(3):346-55. Epub 2014 Jul 18.

Department of Haematology, Royal Liverpool and Broadgreen University Hospitals NHS Trust, Liverpool, UK; Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bjh.13043DOI Listing
November 2014

Motility and trafficking in B-cell non-Hodgkin's lymphoma (Review).

Int J Oncol 2014 Jul 23;45(1):5-12. Epub 2014 Apr 23.

Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L69 3GA, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.3892/ijo.2014.2395DOI Listing
July 2014

Pharmacogenetics in the treatment of chronic lymphocytic leukemia: what does the future hold?

Pharmacogenomics 2014 May;15(7):897-900

Department of Haematology, Royal Liverpool & Broadgreen University Hospitals Trust, Liverpool, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.2217/pgs.14.60DOI Listing
May 2014

Rituximab plus chlorambucil as first-line treatment for chronic lymphocytic leukemia: Final analysis of an open-label phase II study.

J Clin Oncol 2014 Apr 17;32(12):1236-41. Epub 2014 Mar 17.

Peter Hillmen, Abraham Varghese, and Andy Rawstron, St James's Institute of Oncology; Dena Cohen, University of Leeds, Leeds; John G. Gribben, Barts and the London School of Medicine; Claire E. Dearden, Royal Marsden Hospital; Amit Nathwani, University College London, London; George A. Follows, Addenbrooke's Hospital, Cambridge; Donald Milligan, Heartlands Hospital, Birmingham; Hazem A. Sayala, Hull and East Yorkshire Hospitals, Hull; Paul Moreton, Pinderfields General Hospital, Wakefield; David G. Oscier, Royal Bournemouth Hospital, Bournemouth; Daniel B. Kennedy, Leicester Royal Infirmary, Leicester; Andrew R. Pettitt, Royal Liverpool and Broadgreen University Hospitals National Health Service Trust, Liverpool; Christopher F.E. Pocock, East Kent Hospitals, Canterbury, United Kingdom; and Stephan Oertel, F. Hoffmann-La Roche, Basel, Switzerland.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2013.49.6547DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4876343PMC
April 2014

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia.

N Engl J Med 2014 Mar 22;370(11):997-1007. Epub 2014 Jan 22.

Weill Cornell Medical College (R.R.F.), Memorial Sloan-Kettering Cancer Center (A.D.Z.), the Department of Medicine, and Columbia University Medical Center (N.L.) - all in New York; U.S. Oncology Research, Springfield, OR (J.P.S.); Stanford University School of Medicine, Stanford (S.E.C.), and Gilead Sciences, Foster City (M.A., D.M.J., L.L.M., D.L., T.M.J., R.D.D.) - both in California; Lombardi Comprehensive Cancer Center, Georgetown University Hospital, Washington, DC (B.D.C.); Fred Hutchinson Cancer Research Center, University of Washington, Seattle (J.M.P.); St. James's University Hospital, Leeds (P.H.), and Royal Liverpool University Hospital, Liverpool (A.R.P.) - both in the United Kingdom; Hofstra North Shore-LIJ School of Medicine, New Hyde Park, New York (J.C.B.); University of California San Diego, Moores Cancer Center, La Jolla (T.J.K.); Sarah Cannon Research Institute, Nashville (I.F.); Universita Vita-Salute San Raffaele, Instituto Scientifico San Raffaele, Milan (P.G.); David Geffen School of Medicine, University of California Los Angeles, Los Angeles (H.E.); Florida Cancer Specialists, Englewood (T.E.); Centre Hospitalier Lyon-Sud, Pierre-Bénite, France (B.C.); Robert H. Lurie Comprehensive Cancer Center, Feinberg School of Medicine, Northwestern University, Chicago (S.M.); University of Ulm, Ulm (S.S.), and University of Cologne, Cologne (P.C., M.H.) - both in Germany; and University of Texas M.D. Anderson Cancer Center, Houston (S.M.O.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1315226DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4161365PMC
March 2014

Chemokine unresponsiveness of chronic lymphocytic leukemia cells results from impaired endosomal recycling of Rap1 and is associated with a distinctive type of immunological anergy.

J Immunol 2013 Aug 26;191(3):1496-504. Epub 2013 Jun 26.

Department of Molecular and Clinical Cancer Medicine, University of Liverpool, Liverpool L69 3GA, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4049/jimmunol.1203484DOI Listing
August 2013

Lenalidomide can be highly effective in chronic lymphocytic leukaemia despite T-cell depletion and deletion of chromosome 17p.

Eur J Haematol 2011 Oct 11;87(4):372-5. Epub 2011 Aug 11.

Directorate of Clinical Haematology, Royal Liverpool & Broadgreen University Hospitals NHS Trust, Liverpool, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/j.1600-0609.2011.01667.xDOI Listing
October 2011

Akt is activated in chronic lymphocytic leukemia cells and delivers a pro-survival signal: the therapeutic potential of Akt inhibition.

Haematologica 2010 Jan 27;95(1):110-8. Epub 2009 Aug 27.

Division of Hematology, School of Cancer Studies, University of Liverpool, 3 Floor Duncan Building, Daulby Street, Liverpool L69 3GA, UK.

View Article

Download full-text PDF

Source
http://www.haematologica.org/cgi/doi/10.3324/haematol.2009.0
Publisher Site
http://dx.doi.org/10.3324/haematol.2009.010272DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2805750PMC
January 2010

Glucocorticoid-based combination therapy for chronic lymphotic leukemia: new tricks for an old dog.

Authors:
Andrew R Pettitt

Leuk Lymphoma 2008 Oct;49(10):1843-5

Division of Haemotology, University of Liverpool School of Cancer Studies, Royal Liverpool University Hospital, Liverpool, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/10428190802455883DOI Listing
October 2008

Basic fibroblast growth factor suppresses p53 activation in the neoplastic cells of a proportion of patients with chronic lymphocytic leukaemia.

Oncogene 2005 Oct;24(45):6855-60

Department of Haematology, Royal Liverpool University Hospital, Level 2 Ducan Building, Prescot Street, Liverpool, Merseyside L7 8XP, UK.

View Article

Download full-text PDF

Source
http://www.nature.com/articles/1208895
Publisher Site
http://dx.doi.org/10.1038/sj.onc.1208895DOI Listing
October 2005

The ATR-p53 pathway is suppressed in noncycling normal and malignant lymphocytes.

Oncogene 2004 Mar;23(10):1911-21

Department of Haematology, Royal Liverpool University Hospital, Prescot Street, Liverpool L7 8XP, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1038/sj.onc.1207318DOI Listing
March 2004

Mechanism of action of purine analogues in chronic lymphocytic leukaemia.

Authors:
Andrew R Pettitt

Br J Haematol 2003 Jun;121(5):692-702

Department of Haematology, Royal Liverpool University Hospital, Liverpool, UK.

View Article

Download full-text PDF

Source
June 2003

Correlation between cell size and CD38 expression in chronic lymphocytic leukaemia.

Leuk Lymphoma 2003 May;44(5):797-800

Department of Haematology, Level 2 Duncan Building, Royal Liverpool University Hospital, Liverpool L7 8XP, UK.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1080/1042819031000068034DOI Listing
May 2003

Response of hairy cells to IFN-alpha involves induction of apoptosis through autocrine TNF-alpha and protection by adhesion.

Blood 2002 Jul;100(2):647-53

Department of Haematology, University of Liverpool, United Kingdom.

View Article

Download full-text PDF

Source
July 2002

Cytoprotective antioxidant activity of serum albumin and autocrine catalase in chronic lymphocytic leukaemia.

Br J Haematol 2002 Feb;116(2):316-28

Department of Haematology, Royal Liverpool University Hospital, Liverpool, UK.

View Article

Download full-text PDF

Source
February 2002